CClinicalTrials.gg
CompletedNCT06496204SPAFUpdated Aug 13, 2026

Swedish Physical Activity and Fitness Longitudinal Study

An observational study in Sarcopenia, Physical Fitness and Muscle Strength, sponsored by Karolinska Institutet. Completed at 1 site in Sweden. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Karolinska Institutet · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
429
Sex
All
01

Study summary

Aging means loss of strength, which can affect the ability to lead an active life and be independent. Physical activity can counteract the loss of strength to some extent, but individual differences are large and the mechanisms are partly unknown. The hypothesis is that changes in the innervation and composition of the muscle may explain the individual differences in strength loss. A group of Swedish men and women have participated in this study of physical performance for almost 50 years, since they were 16 years old. The project will improve the understanding of muscle aging. The findings may help to develop strategies to counteract muscle loss and enable healthy aging and to promote physical activity throughout life

Read the detailed description

STUDY MATERIALS: The investigators have finished the latest data collection performed at age 63 in 2021-2022 of the human longitudinal cohort study SPAF-1958. At baseline, in 1974, six geographic areas in Sweden were systematically selected. In each area, one upper secondary school was randomly selected, from which 429 (224 male, and 205 female) pupils in the lowest grade level were randomly selected to be included in the study. The entire cohort was invited for questionnaire and testing at age 16, 34 and 52 and 63 years. DATA COLLECTION: Questionnaire: The questionnaire included questions about lifestyle factors such as physical activity, dietary habits, smoking, alcohol consumption.

The questionnaire also included questions about health, disease, medication, and personal traits. Testing of physical performance: Some tests for physical performance were used at all data collections from 16 to 63 years, including aerobic capacity and muscle static and dynamic strength. Specific tests assessing muscle function in relation to muscle weakness were added to the testing at 63 years. Venous blood was drawn for analysis of standard health variables as well as extended studying of endocrine profile and inflammatory cell profile. The muscle size of two selected muscles on the leg were estimated by ultrasound. Body composition and muscle size were determined in 60 subjects by MR imaging of the whole body. Testing of neurological status: Motor nerve conductions studies (NCS) were performed on the right median and ulnar, and bilaterally on tibial, and peroneal nerves. Sensory NCS were performed on the right median, ulnar, and superficial radial nerves, and bilaterally on the sural and superficial peroneal nerves. Motor and sensory conduction velocities, proximal and distal compound muscle action potentials (CMAP), and sensory nerve action potentials (SNAP) were recorded. For motor unit number estimation (MUNE) m. tibialis anterior (TA) and m. abductor policies brevis (ABP) were tested by electrical stimulation of the median and peroneal nerve, respectively. MUNE was obtained by dividing the size of the maximal CMAP by the size of the mean surface-recorded single motor unit potential (S-MUP). MUNE=Max CMAP (area) / Mean SMUP (area). To define small fibre neuropathy a skin biopsy was collected to measure the density of small fibre epidermal innervation. Skeletal muscle samples were obtained with a Bergström biopsy needle from m. vastus lateralis and were snap-frozen in liquid nitrogen cooled isopentane and stored at -80°C. To maximize the possibility to include high number of neuromuscular transmission junctions (endplates) in the muscle biopsy, the optimal biopsy site was determined by location of maximal twitch response to electrical nerve stimulation. Furthermore, the needle was re-directed after penetration of the skin to cut myofibers as longitudinally as possible. This approach was chosen to optimize the conditions for analyses of the NMJ.

ANALYSES OF SKELETAL MUSCLE: The data collection at 63 years will be completed with morphological and immune-/enzyme-histochemical analysis of 120 muscle biopsies. Disruption of axon and motor unit integrity may initiate and drive the wasting and functional impairment of skeletal muscles during aging. To test our hypothesis of the neurogenic impact on loss of muscle strength, the investigators will examine and compare biopsies of skeletal muscle from age 27 and 63 in the same individuals. This part of the analyses will focus on fibre type transitions (myosin subtypes), change in fibre-size and clustering of fibre types with advancing age (a sign of denervation followed by re-innervation). For the biopsies at age 63, after cryo-sectioning, muscle sections will be stained using enzyme histochemistry, histological stains, and immunohistochemistry, followed by confocal microscopy imaging. From 27 years of age there are sectioned and stained muscle tissue available from a subgroup of the cohort, to compare with the characteristics of the muscle at 63 years. These samples need to be digitalised in our microscopy and imaging analysis facility before analyses of fibre clustering. Also, the muscle biopsies harvested at age 63 will be analysed for NMJ by staining for acetylcholine (presynaptic), CHARNs (postsynaptic receptors), terminal Schwann cells, and the parallel autonomic innervation (norepinephrine). The investigators will use a panel of antibodies including markers of axonal and terminal Schwann cell involvement in re-innervation. The cryo-sectioning and refinement/validation of the labelling protocols will be performed by HR in collaboration with BU, TG and MW. HR has a full-time position in the group and is specialized in these methods. In addition, the investigators apply for funding 1 month for a research assistant to digitalise and analyse muscle fibre composition from age 27. ANALYSES OF MAGNETIC RESONANCE IMAGES Subjects have been scanned with a 1.5 Tesla Siemens camera at Karolinska University Hospital in Huddinge. The investigators used a modified 2-point Dixon fat-water sequence that scans the entire body in 6 minutes. Automatic image analysis will be performed using AMRA™ segmentation software (Advanced MR Analytics AB, Linköping, Sweden). The data provided include adipose and muscle tissue of the entire body (from neck to knee), muscle volume and muscle fat infiltration in the anterior and posterior thigh muscles, and subcutaneous adipose tissue in the abdomen and fat content of the liver. The advantage of the results of the MRI technique is not only the very high reproducibility, but also the fact that it can be adjusted to body size using muscle-specific z-scores for volume and fat infiltration. This has been a major problem in the past, as essentially small people were much more easily classified as sarcopenic, while overweight/obese people were rarely classified as having too little muscle mass. The standardized z-score has been calculated for different age groups based on over 10 000 people scanned in the UK Biobank. Both muscle volume value and fat infiltration of muscle were associated with physical function, with the strongest predictive value when low muscle volume was combined with high fat infiltration, i.e. adverse muscle composition.

02

Conditions studied

  • Sarcopenia
  • Physical Fitness
  • Muscle Strength
  • Dynapenia
  • Aerobic Fitness

Browse trials for

Keywords

  • physical fitness
  • aerobic capacity
  • skeletal muscle
  • neuromuscular junction
  • motor unit
  • ageing
  • longitudinal study
  • immunohistochemistry
  • UPS system
03

In context

Sarcopenia

1,208 studies on the registry are indexed under Sarcopenia; 402 are open to participants now.

This study's enrollment of 429 is above the median of 120 across 419 observational studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,113 studies on the registry; 267 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

se above

Inclusion criteria

Belonging to the 0.5% of all pupils who entered secondary high school in Sweden in 1974 and attended one of the systematically selected secondary high schools, and was belonging to the systematically selected pupils.

Exclusion criteria

Exclusion Criteria:

  • not being part of the inclusion criteria
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
429 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • SPAF

    At the beginning of the study, in 1974, a group of 429 (224 males, and 205 females) of pupils at secondary high school in Sweden was systematically selected: The country was stratified into six regions with a similar population size and climate. In each region, one or more secondary high schools were randomly selected. At each school, the number of pupils was selected in proportion to the distribution of girls and boys in secondary high school, the number of pupils in the region, and the proportion of pupils in each school program (theoretical three-year program to prepare for higher studies or practical two-year program to prepare for working life). Individual subjects were then randomly selected at each school based on these criteria and are representative of 16-year-old girls and boys attending secondary high school in Sweden. All participants have been invited to followups at age 34, 52 and 63 years

06

What researchers measure

Primary outcomes

  1. Aerobic capacity

    Submaximal ergometer test estimating maximal oxygen consumption (L/min)

    Time frame: through study completion, an average of 70 year

  2. Skeletal muscle fiber distribution

    Proportion of type I and type II skeletal muscle fibers from biopsies

    Time frame: through study completion, an average of 70 year

  3. Sargent Jump

    Vertical jump (cm)

    Time frame: through study completion, an average of 70 year

  4. Muscular endurance

    Bench press test with women lifting 12 kg and med 20 kg at a pace of 25 lifts per minute until exhaustion

    Time frame: through study completion, an average of 70 year

Secondary outcomes

  1. physical activity

    Questionnaire: "Are you leisure-time physically active" (yes or no)

    Time frame: through study completion, an average of 70 year

  2. Educational level

    Questionnaire: Do you have a university education? Yes or no. Self reported

    Time frame: through study completion, an average of 70 year

07

Study locations

1 site
  • Karolinska institutet
    Stockholm, 14152, Sweden
08

References and documents

Publications

  • Westerstahl M, Jornaker G, Jansson E, Aasa U, Ingre M, Pourhamidi K, Ulfhake B, Gustafsson T. Rise and Fall of Physical Capacity in a General Population: A 47-Year Longitudinal Study. J Cachexia Sarcopenia Muscle. 2025 Dec;16(6):e70134. doi: 10.1002/jcsm.70134. PubMed 41243424 ↗

Individual participant data

Plan to share: No — Publication data can be shared

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06496204
Lead sponsor
Karolinska Institutet
Collaborators
Swedish Research Council for Sport Science, The Swedish Research Council
Responsible party
Maria Westerstahl (Principal Investigator, Karolinska Institutet) — Principal investigator
First posted
Jul 11, 2024
Start date
Mar 22, 2021
Primary completion
Jun 8, 2022
Completion
Jun 8, 2022
Last update
Aug 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion